In 2012, researchers at the Scripps Research Institute quietly published findings on a compound that could make mice run farther, lose fat faster, and process energy more efficiently — all without changing their diet or exercise habits. That compound was SR9009, a synthetic REV-ERB agonist that has since captured the attention of researchers, biohackers, and competitive sports governing bodies alike. WADA banned it before human trials were even complete. That says something.
What Is SR9009?
SR9009 is a synthetic agonist of REV-ERBα and REV-ERBβ — two nuclear receptors that serve as master regulators of the body’s circadian clock, metabolic function, and mitochondrial biogenesis. Despite being frequently grouped alongside SARMs in research communities, SR9009 is not a selective androgen receptor modulator. It operates through an entirely different pathway, binding directly to REV-ERB proteins rather than androgen receptors.
Developed by Thomas Burris, Ph.D., and his team at Scripps, SR9009 was originally designed to study how circadian rhythms influence metabolism. What emerged from those studies was far more interesting than expected: a compound that could fundamentally alter how cells generate and consume energy.
Research Overview
The bulk of SR9009 research has been conducted in animal models, with the landmark study published in Nature Medicine in 2013 by Cho et al. demonstrating that REV-ERB agonism produced significant metabolic effects in mice. Key findings from peer-reviewed preclinical literature include:
A 2013 Nature Medicine study showed that SR9009 activation of REV-ERBα led to decreased fat storage, improved mitochondrial count in skeletal muscle, and enhanced running endurance by up to 50% in mice. A subsequent 2014 study in Cell Metabolism confirmed REV-ERB’s central role in lipid and glucose metabolism regulation. Researchers have also explored SR9009 in cardiovascular health models, finding that REV-ERB agonism reduced cardiac inflammation markers.
Community discussion and anecdotal research logs can be found across forums such as r/PeptideScience and r/sarmssourcetalk, where researchers document their self-experimentation protocols and observations.
Potential Benefits Studied
- Enhanced endurance: Preclinical models showed up to 50% improvement in running capacity, attributed to increased mitochondrial density and oxidative capacity in skeletal muscle.
- Accelerated fat metabolism: REV-ERB activation appears to upregulate fatty acid oxidation while simultaneously reducing fat storage enzyme activity, leading to significant reduction in adiposity in obese animal models.
- Mitochondrial biogenesis: SR9009 promotes the creation of new mitochondria in muscle tissue, potentially improving the body’s fundamental energy production capacity.
- Anti-inflammatory effects: Several studies have noted reduced inflammatory markers in SR9009-treated subjects, with potential implications for cardiovascular and metabolic health.
- Glucose regulation: REV-ERB agonism has been linked to improved glucose uptake and reduced hepatic glucose production in preclinical models.
- Circadian rhythm modulation: As a direct regulator of the biological clock, SR9009 may influence sleep/wake cycles and the timing of metabolic processes.
Dosage and Administration
SR9009’s primary pharmacological challenge is its short half-life of approximately 4–5 hours, which necessitates multiple administrations per day for sustained REV-ERB engagement. In animal models, dosing was typically weight-based at 100 mg/kg. Community researchers have explored oral dosing in the range of 20–40 mg per day split across 3–4 administrations, as well as subcutaneous injection protocols that may improve bioavailability. The injectable 50MG/ML concentration is of particular interest to researchers because oral bioavailability of SR9009 has been questioned in some analyses — a topic of ongoing debate. Typical research cycles range from 4 to 8 weeks, with no PCT required given SR9009’s non-hormonal mechanism of action.
Where to Find SR9009 for Research
Combat Research offers SR9009 in a 50MG/ML injectable preparation for research purposes. The full product listing is available at combatresearch.is/product/sr9009-50mg-ml/.
Conclusion
SR9009 represents one of the more scientifically fascinating research compounds to emerge from modern chronobiology and metabolic science. Its ability to target REV-ERB nuclear receptors — directly influencing circadian rhythm, fat oxidation, mitochondrial density, and endurance — makes it a compound of significant academic interest. While human clinical data remains limited and no approved therapeutic applications exist, the preclinical evidence has been compelling enough to prompt preemptive regulatory action from WADA and other sports governing bodies. For researchers studying metabolic disease, performance physiology, and circadian biology, SR9009 remains an active and intriguing subject of inquiry.
Disclaimer
This article is intended for educational and informational purposes only. SR9009 is a research compound that has not been approved for human use by the FDA or any other regulatory authority. This content does not constitute medical advice. Always consult a licensed medical professional before considering any research compound. Combat Research sells SR9009 strictly for laboratory and research purposes.
